Pfizer Inc.’s experimental drug to treat patients with moderate-to-severe atopic dermatitis met the main goals of improving symptoms in adult patients compared to a rival treatment from Regeneron Pharmaceutical Inc.
During the Digestive Disease Week meeting, AbbVie presented late-breaking data analyses that showed both doses of Skyrizi met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo in two Phase III studies. The Lancet published results from pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with mild to severe atopic dermatitis who were candidates for systemic treatment.
Sanofi and Regeneron’s Dupixent product won approval from the European Commission to treat children aged 6-11 years suffering from severe atopic dermatitis, often known as eczema.
Pfizer received positive top-line results from the Phase III JADE REGIMEN study, examining the investigational oral once-daily Janus kinase 1 (JAK1) inhibitor abrocitinib for the treatment of severe atopic dermatitis.
AbbVie’s Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in a second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.
A look at the U.S. Food and Drug Administration’s drug approval review calendar.
Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.
Incyte’s ruxolitinib cream hit the drug’s primary endpoint in the Phase III TRuE-AD2 trial of atopic dermatitis in adolescents and adults. Incyte and Eli Lilly announced topline results from the Phase III trial (FREEZE-AD4) of baricitinib in topical corticosteroids for the treatment of adults with moderate to severe atopic dermatitis who did not respond to treatment with cyclosporine.
AnaptysBio Inc. announced topline data from the clinical-stage biotechnology company’s ATLAS Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in 300 adults treated with etokimab in moderate-to-severe atopic dermatitis.
Singapore-based ASLAN Pharmaceuticals amended the company’s global license agreement with CSL Limited to gain full rights to the fully human monoclonal antibody ASLAN004 being developed for atopic dermatitis and other inflammatory diseases.